Silver Book Fact

Drug-resistant MRSA expensive to treat

As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.

Mauldin, Patrick D., Cassandra D. Salgado, Ida Solhoj Hansen, Darshana T. Durup, and John A. Bosso. Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic Resistant Gram-Negative Bacteria. Antimicrob Agents Chemother. 2009; 54(1): 109-15. http://aac.asm.org/content/54/1/109.full

Reference

Title
Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic Resistant Gram-Negative Bacteria
Publication
Antimicrob Agents Chemother
Publication Date
2009
Authors
Mauldin, Patrick D., Cassandra D. Salgado, Ida Solhoj Hansen, Darshana T. Durup, and John A. Bosso
Volume & Issue
Volume 54, Issue 1
Pages
109-15
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Drug-resistant MRSA expensive to treat
    As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.  
  • C. difficile-related deaths on the rise
    Between 1999 and 2004, C. difficile-related deaths in the U.S. increased 35% each year.  
  • 1 in 4 inpatient pneumonia hospitalizations due to HAIs
    In one study, one in four inpatient pneumonia hospitalizations were from health-care-associated pneumonia.  
  • Significant increase of penicillin-resistant Streptococcus penumoniae
    High-level penicillin-resistant Steptococcus pneumoniae increased 1,000-fold over 17 years.  
  • Sepsis hospitalization rate increases with age
    The rate of hospitalization for sepsis/septicemia in 2008 was around 30 times higher for patients ages 85 and older, than for those under the age of 65.